Emotion Regulation Skills Training for Individuals With MS and Their Support Partners
NCT ID: NCT03934489
Last Updated: 2021-03-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2020-01-07
2021-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Remediation of Emotional Processing Deficits in MS
NCT03373344
A Social Emotion Regulation Intervention in MS
NCT03951974
Meeting an Unmet Need in Multiple Sclerosis
NCT05953519
Remediation of Emotional Deficits in Multiple Sclerosis and Traumatic Brain Injury
NCT04408274
MS Symptom Management Study
NCT02474940
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PERSIST
Participants will receive Partnered Emotion Regulation Skills Intervention and Support.
PERSIST
12-week group, adapted from Dialectical Behavior Therapy, that focuses on emotion regulation skills training and practice.
Facilitated Peer Support
Participants will undergo a 12-week group intervention, adapted from community-based peer support groups, that focuses on participant-generated topics and facilitated discussion.
Facilitated Peer Support
12-week group, adapted from community-based peer support groups, that focuses on participant-generated topics and facilitated discussion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PERSIST
12-week group, adapted from Dialectical Behavior Therapy, that focuses on emotion regulation skills training and practice.
Facilitated Peer Support
12-week group, adapted from community-based peer support groups, that focuses on participant-generated topics and facilitated discussion.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* able to speak/read in English
* able to commit to attending at least 9 of the 12 weekly group sessions
* individuals with MS must be relapse/exacerbation-free for at least 1 month
* support partners must score at least 8 on the HADS-D or HADS-A
* individuals with MS must score a least 11 on the HADS-D or HADS-A
Exclusion Criteria
* unable to speak/read in English
* unable to commit to attending at least 9 of the 12 weekly group sessions
* MS relapse within 1 month
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Multiple Sclerosis Society
OTHER
Johns Hopkins University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abbey Hughes, PhD
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins University
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PP-1804-30860
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
IRB00199623
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.